862 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/358874/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-358874 Mar 12, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC http://www.zacks.com/stock/news/358374/roches-rhhby-tecentriq-gets-ec-nod-for-first-line-nsclc?cid=CS-ZC-FT-358374 Mar 08, 2019 - Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA http://www.zacks.com/stock/news/357971/roches-rhhby-snda-for-flu-candidate-accepted-by-the-fda?cid=CS-ZC-FT-357971 Mar 06, 2019 - The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda http://www.zacks.com/stock/news/357700/merck-gets-chmp-nod-for-six-week-dosing-option-of-keytruda?cid=CS-ZC-FT-357700 Mar 05, 2019 - Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up http://www.zacks.com/stock/news/357477/endo-endp-q4-earnings-revenues-beat-estimates-shares-up?cid=CS-ZC-FT-357477 Mar 01, 2019 - Endo's (ENDP) earnings and revenues top expectations in the fourth quarter.
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares http://www.gurufocus.com/news/821392/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-77-million-of-shares Feb 22, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares, Stocks: MRK, release date:Feb 22, 2019
Merck to Buy Immunotherapy Developer Immune Design for $300M http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-ZC-FT-356654 Feb 22, 2019 - Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
What's in the Cards for Perrigo (PRGO) This Earnings Season? http://www.zacks.com/stock/news/356476/whats-in-the-cards-for-perrigo-prgo-this-earnings-season?cid=CS-ZC-FT-356476 Feb 22, 2019 - Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.

Pages: 1...56789101112131415...87

<<<Page 10>